CA2613187A1 - Detection of a target antigen irrespective of the presence or absence of a corresponding therapeutic antibody - Google Patents

Detection of a target antigen irrespective of the presence or absence of a corresponding therapeutic antibody Download PDF

Info

Publication number
CA2613187A1
CA2613187A1 CA002613187A CA2613187A CA2613187A1 CA 2613187 A1 CA2613187 A1 CA 2613187A1 CA 002613187 A CA002613187 A CA 002613187A CA 2613187 A CA2613187 A CA 2613187A CA 2613187 A1 CA2613187 A1 CA 2613187A1
Authority
CA
Canada
Prior art keywords
antibody
therapeutic antibody
target antigen
sample
therapeutic
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002613187A
Other languages
English (en)
French (fr)
Inventor
Helmut Lenz
Werner Scheuer
Martina Thier
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
F Hoffmann La Roche AG
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2613187A1 publication Critical patent/CA2613187A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/536—Immunoassay; Biospecific binding assay; Materials therefor with immune complex formed in liquid phase

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Chemical & Material Sciences (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • Cell Biology (AREA)
  • Food Science & Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Microbiology (AREA)
  • General Health & Medical Sciences (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
CA002613187A 2005-07-06 2006-07-05 Detection of a target antigen irrespective of the presence or absence of a corresponding therapeutic antibody Abandoned CA2613187A1 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
EP05014618 2005-07-06
EP05014618.2 2005-07-06
EP06004447.6 2006-03-06
EP06004447 2006-03-06
PCT/EP2006/006524 WO2007003420A1 (en) 2005-07-06 2006-07-05 Detection of a target antigen irrespective of the presence or absence of a corresponding therapeutic antibody

Publications (1)

Publication Number Publication Date
CA2613187A1 true CA2613187A1 (en) 2007-01-11

Family

ID=36922121

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002613187A Abandoned CA2613187A1 (en) 2005-07-06 2006-07-05 Detection of a target antigen irrespective of the presence or absence of a corresponding therapeutic antibody

Country Status (19)

Country Link
US (1) US20070009976A1 (2)
EP (2) EP1902315A1 (2)
JP (1) JP2008545145A (2)
KR (1) KR20080016939A (2)
AR (1) AR053948A1 (2)
AU (1) AU2006265275A1 (2)
BR (1) BRPI0612591A2 (2)
CA (1) CA2613187A1 (2)
CR (1) CR9635A (2)
EC (1) ECSP088081A (2)
IL (1) IL188317A0 (2)
MA (1) MA29730B1 (2)
MX (1) MX2008000277A (2)
MY (1) MY157955A (2)
NO (1) NO20076662L (2)
NZ (1) NZ564471A (2)
RU (1) RU2008103608A (2)
TW (1) TWI312864B (2)
WO (1) WO2007003420A1 (2)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2407556C (en) * 2000-05-19 2011-06-21 Genentech, Inc. Gene detection assay for improving the likelihood of an effective response to an erbb antagonist cancer therapy
DK1771482T3 (da) * 2004-07-22 2014-10-20 Genentech Inc HER2-antistofsammensætning
WO2006039486A2 (en) 2004-10-01 2006-04-13 The Board Of Trustees Of The Leland Stanford Junior University Imaging arrangements and methods therefor
JO3000B1 (ar) * 2004-10-20 2016-09-05 Genentech Inc مركبات أجسام مضادة .
EP1850874B1 (en) 2005-02-23 2013-10-16 Genentech, Inc. Extending time to disease progression or survival in ovarian cancer patients using pertuzumab
PE20070207A1 (es) * 2005-07-22 2007-03-09 Genentech Inc Tratamiento combinado de los tumores que expresan el her
WO2007092581A2 (en) 2006-02-07 2007-08-16 The Board Of Trustees Of The Leland Stanford Junior University Correction of optical aberrations
US8358354B2 (en) 2009-01-26 2013-01-22 The Board Of Trustees Of The Leland Stanford Junior University Correction of optical abberations
SI2132573T1 (sl) 2007-03-02 2014-07-31 Genentech, Inc. Napovedovanje odziva na inhibitor dimerizacije HER na osnovi nizke ekspresije HER3
TWI472339B (zh) 2008-01-30 2015-02-11 Genentech Inc 包含結合至ｈｅｒ２結構域ii之抗體及其酸性變異體的組合物
BRPI0812682A2 (pt) 2008-06-16 2010-06-22 Genentech Inc tratamento de cáncer de mama metastático
IL301603A (en) 2011-10-14 2023-05-01 Genentech Inc Pertuzumab, trastuzumab, docetaxel and carboplatin for use in the preoperative treatment of a patient
KR101327542B1 (ko) * 2012-03-15 2013-11-08 광주과학기술원 양자점 기반의 경쟁 면역분석법 및 다중 유세포 분석법을 이용한 시료 중 오염물질의 검출 방법
AU2012232949B2 (en) * 2012-09-28 2014-07-03 Willowtree Holdings Pty Ltd Temporary bulkhead
MX368259B (es) 2013-04-16 2019-09-25 Genentech Inc Variantes de pertuzumab y su evaluacion.
KR20160141857A (ko) 2014-04-25 2016-12-09 제넨테크, 인크. 트라스투주맙-mcc-dm1 및 퍼투주맙을 이용하는 초기 유방암의 치료방법
WO2016196373A2 (en) 2015-05-30 2016-12-08 Genentech, Inc. Methods of treating her2-positive metastatic breast cancer
WO2017087280A1 (en) 2015-11-16 2017-05-26 Genentech, Inc. Methods of treating her2-positive cancer
EP3562844A1 (en) 2016-12-28 2019-11-06 Genentech, Inc. Treatment of advanced her2 expressing cancer
TW202508629A (zh) 2017-01-17 2025-03-01 美商建南德克公司 皮下her2抗體調配物
PT3589661T (pt) 2017-03-02 2024-01-29 Genentech Inc Tratamento com adjuvante de cancro da mama positivo para her2
WO2018200505A1 (en) 2017-04-24 2018-11-01 Genentech, Inc. Erbb2/her2 mutations in the transmbrane or juxtamembrane domain
JP2023532122A (ja) 2020-06-29 2023-07-26 ジェネンテック， インコーポレイテッド ペルツズマブにトラスツズマブを加えた固定用量配合剤

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2095818B (en) 1981-03-27 1985-10-02 Exxon Research Engineering Co Staged adsorption/resorption heat pump
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
EP1400536A1 (en) * 1991-06-14 2004-03-24 Genentech Inc. Method for making humanized antibodies
AU4025193A (en) 1992-04-08 1993-11-18 Cetus Oncology Corporation Humanized C-erbB-2 specific antibodies
KR20060079258A (ko) 1996-10-18 2006-07-05 제넨테크, 인크. 항-ＥｒｂＢ２ 항체
JP4424987B2 (ja) * 2001-09-20 2010-03-03 ボード オブ リージェンツ， ザ ユニバーシティ オブ テキサス システム Ｅｌｉｓａアッセイを用いた循環する治療抗体、抗原および抗原／抗体複合体の測定
WO2004008099A2 (en) * 2002-07-15 2004-01-22 Genentech, Inc. METHODS FOR IDENTIFYING TUMORS THAT ARE RESPONSIVE TO TREATMENT WITH ANTI-ErbB2 ANTIBODIES

Also Published As

Publication number Publication date
RU2008103608A (ru) 2009-08-20
JP2008545145A (ja) 2008-12-11
EP1902315A1 (en) 2008-03-26
IL188317A0 (en) 2008-04-13
BRPI0612591A2 (pt) 2010-11-23
MX2008000277A (es) 2008-03-24
KR20080016939A (ko) 2008-02-22
MA29730B1 (fr) 2008-09-01
NO20076662L (no) 2008-04-03
EP2194380A3 (en) 2010-07-14
TW200741203A (en) 2007-11-01
TWI312864B (en) 2009-08-01
NZ564471A (en) 2010-04-30
MY157955A (en) 2016-08-30
CR9635A (es) 2008-02-20
ECSP088081A (es) 2008-02-20
AR053948A1 (es) 2007-05-23
WO2007003420A1 (en) 2007-01-11
AU2006265275A1 (en) 2007-01-11
EP2194380A2 (en) 2010-06-09
US20070009976A1 (en) 2007-01-11

Similar Documents

Publication Publication Date Title
US20070009976A1 (en) Detection of a target antigen irrespective of the presence or absence of a corresponding therapeutic antibody
US7279287B2 (en) Analytical method
JP2011039072A (ja) 実験動物における治療抗体の検出
US20180113127A1 (en) Immunoassay method and assay reagent used in said method
US20180088118A1 (en) Immunological measurement method for l-fabp and measurement reagent used in said method
EP2707720B1 (en) Diagnosis and prognosis of triple negative breast and ovarian cancer
CN101213450A (zh) 不论存在或不存在相对应的治疗用抗体而检测靶抗原
Fetsch et al. The effects of antibody clone and pretreatment method on the results of HER2 immunostaining in cytologic samples of metastatic breast cancer: A query and a review of the literature
HK1115446A (en) Detecting of a target antigen irrespective of the presenace or absence of a corresponding therapeutic antibody
US20090029394A1 (en) Novel Assay for the Detection of an Antibody Bound to a Cell Membrane Receptor
US20250244337A1 (en) Compositions and methods for identifying subjects who may benefit from treatment with therapeutic agents
CN113125743B (zh) 一种超敏心肌肌钙蛋白i检测方法和试剂盒
CN117783526A (zh) 一种定量检测生物体液中热带念珠菌烯醇化酶的方法
US20090291459A1 (en) Hybridoma capable of producing anti-dectin-1 monoclonal antibody
WO2023191046A1 (ja) Ｈｒｇに対するモノクローナル抗体を用いたｈｒｇの測定方法
CN121293356A (zh) FRα单克隆抗体及其应用
Ahmed Elucidation of the Principles

Legal Events

Date Code Title Description
FZDE Discontinued